• News
  • SAN DIEGO
  • BioTech

Lpath reports interim results in cancer drug trial

Lpath Inc. (Nasdaq: LPTN), which specializes in bioactive lipid-targeted therapeutics, has reported interim results in its Phase 2a trial investigating the drug Asonep as a treatment for metastatic renal cell carcinoma.

Asonep has a favorable safety profile thus far, Lpath reports, with no serious adverse events deemed to be drug-related among 26 patients enrolled in the study. The trial, described as a single-arm, open-label trial is targeted at patients that have failed at least one therapy involving a vascular endothelial growth factor inhibitor and no more than one mammalian target of rapamycin (mTOR) inhibitor such as Afinitor, with a maximum of three failed treatments in all.

The patient population is considered "last line," and the literature suggests cancer progression in this population within a one- to two-month time frame.

Lpath reports that the first 17 patients were initiated at a dose of 15 miligrams per kilogram of body weight. Of these "lower-dose" patients, seven had progressive disease at or before the end of four months while eight were progression-free at the four-month mark. Of the eight patients that were stable or better as of the fourth month, two are now in their 15th month on the study, one is in the 13th month and one is in the 10th. An additional patient was stable through month seven, according to Lpath, but then missed six treatments during a vacation and experienced progression shortly thereafter.

The next nine patients were initiated at a dose of 24 miligrams per kilogram of weight. Of those higher-dose patients, four had progressive disease at or before the end of four months while two were progression-free at the four-month mark. The remaining three have not yet reached their four-month mark, but Lpath added that of the two who were progression-free, one was deemed a partial responder per RECIST criteria, which classifies response evaluation criteria in solid tumors. The partial responder designation means that the patient experianced at least a 30 percent decrease in the sum of the longest diameter of target lesions.

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

User Response
0 UserComments

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

Lpath Inc.

Company Website

6335 Ferris Sq. Ste., A
San Diego, CA 92121

Company Trade Data

Stock Symbol Close
Change
Chg %Chg
Volume
52-Week
High Low
LPTN
0.22
  -0.01  
- 4.35%
303,785,000
3.75
0.18

Lpath Inc. Executive(s):

Scott Pancoast

  • Chief Executive Officer, President

Similar Companies

NAICS - 325414 - Biological Product (except Diagnostic) Manufacturing